Chemistry:Mocetinostat

Mocetinostat

Names
Preferred IUPAC name N-(2-Aminophenyl)-4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzamide
Identifiers
CAS Number	726169-73-9 Y
3D model (JSmol)	Interactive image
ChEBI	CHEBI:197437
ChEMBL	ChEMBL272980 N
ChemSpider	8041206 N
IUPHAR/BPS	7008
KEGG	D09641
PubChem CID	9865515
UNII	A6GWB8T96J Y
InChI InChI=1S/C23H20N6O/c24-19-5-1-2-6-21(19)28-22(30)17-9-7-16(8-10-17)14-27-23-26-13-11-20(29-23)18-4-3-12-25-15-18/h1-13,15H,14,24H2,(H,28,30)(H,26,27,29) N Key: HRNLUBSXIHFDHP-UHFFFAOYSA-N N InChI=1/C23H20N6O/c24-19-5-1-2-6-21(19)28-22(30)17-9-7-16(8-10-17)14-27-23-26-13-11-20(29-23)18-4-3-12-25-15-18/h1-13,15H,14,24H2,(H,28,30)(H,26,27,29) Key: HRNLUBSXIHFDHP-UHFFFAOYAW
SMILES C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC3=NC=CC(=N3)C4=CN=CC=C4
Properties
Chemical formula	C23H20N6O
Molar mass	396.454 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YN ?)
Infobox references

Tracking categories (test):

• SizeSet

Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers including follicular lymphoma, Hodgkin's lymphoma and acute myelogenous leukemia.

One clinical trial (for refractory follicular lymphoma) was temporarily put on hold due to cardiac problems but resumed recruiting in 2009.

In 2010 favourable results were announced from the phase II trial for Hodgkin's lymphoma.

MGCD0103 has also been used as a research reagent where blockage of members of the HDAC-family of histone deacetylases is required.

Mechanism of action

It works by inhibiting mainly histone deacetylase 1 (HDAC1), but also HDAC2, HDAC3, and HDAC11.